Second Merck CRISPR Patent Awarded
Anatalia TGN

CRISPR technology is a core competency for Merck, a leading science and technology company that received its first U.S. patent in February 2019 for its proxy-CRISPR technology making CRISPR more efficient, flexible, and specific. The company continues to develop technologies in a range of genome-editing applications, including gene knockout, gene integration, and CRISPR libraries for […]

Read More
Home
CRISPR Screening for Coronavirus
Anatalia TGN

CRISPR screening for coronavirus is in the works.  CRISPR screening helps identify genes that cause diseases such as sickle-cell anemia, cancer, and lung cancer metastasis. The technology enables thousands of genes to be modified, helping scientists identify and assess their function in a single experiment. However, CRISPR screening can only target or edit DNA, which […]

Read More
Home